Eleva Capital SAS Has $1.70 Million Position in BioMarin Pharmaceutical Inc. $BMRN

Eleva Capital SAS increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 33.8% in the third quarter, Holdings Channel.com reports. The fund owned 31,339 shares of the biotechnology company’s stock after purchasing an additional 7,920 shares during the period. BioMarin Pharmaceutical makes up about 0.4% of Eleva Capital SAS’s investment portfolio, making the stock its 10th largest position. Eleva Capital SAS’s holdings in BioMarin Pharmaceutical were worth $1,697,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in BMRN. Clearstead Advisors LLC raised its stake in shares of BioMarin Pharmaceutical by 60.7% in the third quarter. Clearstead Advisors LLC now owns 3,454 shares of the biotechnology company’s stock worth $187,000 after purchasing an additional 1,304 shares during the last quarter. Michels Family Financial LLC purchased a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at $250,000. Asahi Life Asset Management CO. LTD. increased its holdings in BioMarin Pharmaceutical by 19.4% in the 3rd quarter. Asahi Life Asset Management CO. LTD. now owns 6,591 shares of the biotechnology company’s stock worth $357,000 after buying an additional 1,071 shares in the last quarter. Tredje AP fonden raised its position in BioMarin Pharmaceutical by 2.1% in the 3rd quarter. Tredje AP fonden now owns 296,939 shares of the biotechnology company’s stock worth $16,082,000 after buying an additional 6,197 shares during the last quarter. Finally, Stevens Capital Management LP purchased a new position in BioMarin Pharmaceutical in the 3rd quarter worth about $245,000. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Trading Up 1.0%

Shares of BioMarin Pharmaceutical stock opened at $64.08 on Monday. BioMarin Pharmaceutical Inc. has a 1-year low of $50.76 and a 1-year high of $73.51. The company’s fifty day simple moving average is $58.09 and its 200-day simple moving average is $56.02. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.83 and a quick ratio of 3.10. The stock has a market capitalization of $12.31 billion, a PE ratio of 24.09, a P/E/G ratio of 0.70 and a beta of 0.26.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on BMRN shares. Morgan Stanley dropped their price target on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating on the stock in a report on Tuesday, October 28th. Wall Street Zen cut shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Wells Fargo & Company lifted their target price on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Royal Bank Of Canada reissued a “sector perform” rating and set a $66.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. Finally, Canaccord Genuity Group upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and raised their price target for the stock from $84.00 to $98.00 in a research note on Tuesday, January 20th. Fifteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $88.14.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.